Celsion

CLSN NASDAQ
1.740
-0.060
-3.33%
Closed 16:00 07/22 EDT
Open
1.780
Prev Close
1.800
High
1.790
Low
1.710
Volume
80.86K
Avg Vol (3M)
108.92K
52 Week High
3.095
52 Week Low
1.350
% Turnover
0.39%
Market Cap
35.64M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Celsion CLSN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
MORE >

Recently

Name
Price
%Change